Korean MFDS publishes Revision 7 of Comparative Dissolution Test Guideline
Recommendation

20/21 October 2026
Performance Evaluation and Monitoring for compliant Analytical Procedures and Processes
The Korean Ministry of Food and Drug Safety (MFDS) has revised the "Guidelines for Comparative Dissolution Test (Guideline for Civil Petitioners)". A new version (revision 7) dated 18 May 2023 was published.
The document is divided into the following main chapters:
- Overview
- Considerations when Determining the Equivalence of Comparative Dissolution Test Data
- Comparative Dissolution Test Result Report Standard Format
- References
According to the English translation of chapter 1, "the purpose of this guideline is to help applicants or reviewers understand as reference data for preparation of comparative dissolution test result reports required when applying for pharmaceutical product approval/notification (including changes). [...] This guideline is applied to items subject to comparative dissolution testing for new items for approval and notification of pharmaceuticals and items with changes in approval items."
Compared to the previous version, which was published in 2021, the new document contains additional considerations and references when determining equivalence of comparative dissolution test.
The revised guideline in Korean language can be found as a PDF file on the website of the Ministry of Food and Drug Safety.
Related GMP News
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
07.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination
30.09.2026The Relationship between the BP and the Ph. Eur.
30.09.2026New Japanese Pharmacopoeia Drafts (September 2026) Open for Public Comment
30.09.2026EMA publishes final ICH M13B Guideline and Q&A on Bioequivalence

